Twin deals to give NovaDx osteoporosis "monopoly"
This article was originally published in Clinica
Executive Summary
NovaDx International (Canada) has announced two agreements which it claims will give it "an almost exclusive monopoly" on osteoclast-based blood tests for osteoporosis. In addition to a letter of intent signed with Harvard affiliate Forthsyth Dental Centre, the Vancouver company has been granted the right of refusal by the University of Texas to osteoclast proteins identified and developed by Dr G David Roodman.